Posted by Michael Wonder on 12 Oct 2022
‘Current standard for stopping insurance benefits for SMA treatment harsh on adult patients’
12 October 2022 - Spinraza (nusinersen sodium), the first spinal muscular atrophy treatment that won the insurance coverage quickly since its introduction in Korea, is experiencing difficulty expanding its reimbursement standards.
At stake is the “suspension of reimbursement” for spinal muscular atrophy type 3 patients.
